Michal Lips

Michal Lips

Auto-generated profile, based on publicly available information

Michal Lips

Department of Anaesthesia, Resuscitation and Intensive Medicine, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2009 in Diabetes Care
Verified
Journal Article
Open access
JBJan Blaha
Jan Blaha
PKPetr Kopecky
Petr Kopecky
MMMichal Matias
Michal Matias
RHRoman Hovorka
Roman Hovorka
JKJan Kunstyr
Jan Kunstyr
MHMartin Haluzík
Martin Haluzík
OBJECTIVE: We performed a randomized trial to compare three insulin-titration protocols for tight glycemic control (TGC) in a surgical intensive care unit: an absolute glucose (Matias) protocol, a relative glucose change (Bath) protocol, and an enhanced model predictive control (eMPC) algorithm. RESEARCH DESIGN AND METHODS: A total of 120 consecutive patients after cardiac surgery were randomly assigned to the three protocols with a target glycemia range from 4.4 to 6.1 mmol/l. Intravenous insulin was administered continuously or in combination with insulin boluses (Matias protocol). Blood glucose was measured in 1- to 4-h intervals as requested by the protocols. RESULTS: The eMPC algorithm gave the best performance as assessed by time to target (8.8 ± 2.2 vs. 10.9 ± 1.0 vs. 12.3 ± 1.9 h; eMPC vs. Matias vs. Bath, respectively; P < 0.05), average blood glucose after reaching the target (5.2 ± 0.1 vs. 6.2 ± 0.1 vs. 5.8 ± 0.1 mmol/l; P < 0.01), time in target (62.8 ± 4.4 vs. 48.4 ± 3.28 vs. 55.5 ± 3.2%; P < 0.05), time in hyperglycemia >8.3 mmol/l (1.3 ± 1.2 vs. 12.8 ± 2.2 vs. 6.5 ± 2.0%; P < 0.05), and sampling interval (2.3 ± 0.1 vs. 2.1 ± 0.1 vs. 1.8 ± 0.1 h; P < 0.05). However, time in hypoglycemia risk range (2.9–4.3 mmol/l) in the eMPC group was the longest (22.2 ± 1.9 vs. 10.9 ± 1.5 vs. 13.1 ± 1.6; P < 0.05). No severe hypoglycemic episode (<2.3 mmol/l) occurred in the eMPC group compared with one in the Matias group and two in the Bath group. CONCLUSIONS: The eMPC algorithm provided the best TGC without increasing the risk of severe hypoglycemia while requiring the fewest glucose measurements. Overall, all protocols were safe and effective in the maintenance of TGC in cardiac surgery patients.

1 August 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JBJan Bláha
Jan Bláha
MMMiloš Mráz
Miloš Mráz
PKPetr Kopecký
Petr Kopecký
MSMartin Stříteský
Martin Stříteský
MLMichal Lipš
Michal Lipš
MHMartin Haluzík
Martin Haluzík
Tight glucose control (TGC) reduces morbidity and mortality in patients undergoing elective cardiac surgery, but only limited data about its optimal timing are available to date. The purpose of this article was to compare the effects of perioperative vs postoperative initiation of TGC on postoperative adverse events in cardiac surgery patients. This was a single center, single-blind, parallel-group, randomized controlled trial. The setting was an academic tertiary hospital. Participants were 2383 hemodynamically stable patients undergoing major cardiac surgery with expected postoperative intensive care unit treatment for at least 2 consecutive days. Intensive insulin therapy was initiated perioperatively or postoperatively with a target glucose range of 4.4 to 6.1 mmol/L. Adverse events from any cause during postoperative hospital stay were compared. In the whole cohort, perioperatively initiated TGC markedly reduced the number of postoperative complications (23.2% vs 34.1%, 95% confidence interval [CI], 0.60-0.78) despite only minimal improvement in glucose control (blood glucose, 6.6 ± 0.7 vs 6.7 ± 0.8 mmol/L, P < .001; time in target range, 39.3% ± 13.7% vs 37.3% ± 13.8%, P < .001). The positive effects of TGC on postoperative complications were driven by nondiabetic subjects (21.3% vs 33.7%, 95% CI, 0.54-0.74; blood glucose 6.5 ± 0.6 vs 6.6 ± 0.8 mmol/L, not significant; time in target range, 40.8% ± 13.6% vs 39.7% ± 13.8%, not significant), whereas no significant effect was seen in diabetic patients (29.4% vs 35.1%, 95% CI, 0.66-1.06) despite significantly better glucose control in the perioperative group (blood glucose, 6.9 ± 1.0 vs 7.1 ± 0.8 mmol/L, P < .001; time in target range, 34.3% ± 12.7% vs 30.8% ± 11.5%, P < .001). Perioperative initiation of intensive insulin therapy during cardiac surgery reduces postoperative morbidity in nondiabetic patients while having a minimal effect in diabetic subjects.

1 May 2017 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
DRDaniel Rob
Daniel Rob
RŠRudolf Špunda
Rudolf Špunda
JLJarosla Lindner
Jarosla Lindner
VRVilém Rohn
Vilém Rohn
JKJan Kunstýř
Jan Kunstýř
JBJan Belohlavek
Jan Belohlavek

1 October 2014 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MLMichal Lipš
Michal Lipš
MŠMichal Šiller
Michal Šiller
JSJan Strojil
Jan Strojil
KUKarel Urbanek
Karel Urbanek
MBMartin Balík
Martin Balík
HSHana Suchánková
Hana Suchánková

1 October 2011 in Thrombosis Research
Verified
Journal Article
Closed access
FPFerdinand Polak
Ferdinand Polak
IKIvana Kolnikova
Ivana Kolnikova
MLMichal Lips
Michal Lips
APAntonin Parizek
Antonin Parizek
JBJan Blaha
Jan Blaha
MSMartin Stritesky
Martin Stritesky

31 July 2017 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
MLMichal Lipš
Michal Lipš
MMMiloš Mráz
Miloš Mráz
JKJana Kloučková
Jana Kloučková
PKPetr Kopecký
Petr Kopecký
MDMiloš Dobiáš
Miloš Dobiáš
MHMartin Haluzík
Martin Haluzík